MedDataX Logo

AMG 701 Expanded Access Program

NCT ID: NCT05256446

Last Updated: 2024-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

NCT02561962

Multiple Myeloma
COMPLETED PHASE1

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03836053

Relapsed and/or Refractory Multiple Myeloma
TERMINATED PHASE1

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03287908

Relapsed/Refractory Multiple Myeloma
TERMINATED PHASE1

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

NCT03126617

Multiple Myeloma
NO_LONGER_AVAILABLE

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

NCT03445663

Relapsed/ Refractory Multiple Myeloma
TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMG 701

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Eligible Sex

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AMG701 Expanded Access Program

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647 COMPLETED PHASE3
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
NCT02568943 NO_LONGER_AVAILABLE
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
NCT01410500 APPROVED_FOR_MARKETING
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
NCT05908396 TERMINATED PHASE1
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
NCT04754100 COMPLETED PHASE1
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
NCT04771078 AVAILABLE
Expanded Access for CC-4047
NCT03723096 NO_LONGER_AVAILABLE
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
NCT06246162 RECRUITING PHASE1/PHASE2
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
NCT02666209 NO_LONGER_AVAILABLE
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
NCT02541643 NO_LONGER_AVAILABLE
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616 RECRUITING PHASE1/PHASE2
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
NCT00327249 COMPLETED PHASE1/PHASE2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441 NOT_YET_RECRUITING PHASE2
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
NCT00706953 WITHDRAWN PHASE2
Early Patient Access Treatment Use Protocol CA204-220
NCT02856438 NO_LONGER_AVAILABLE
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 RECRUITING
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
NCT00440635 COMPLETED
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524 RECRUITING PHASE2
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
NCT04017130 TERMINATED PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
NCT05646836 ACTIVE_NOT_RECRUITING PHASE1
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01087008 COMPLETED PHASE4
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
NCT01302392 COMPLETED PHASE3
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
NCT05757973 APPROVED_FOR_MARKETING
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
NCT00103662 COMPLETED PHASE3
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
NCT04178902 TERMINATED PHASE1